Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
Journal
European Journal of Cancer
Journal Volume
124
Pages
110-122
Date Issued
2020
Author(s)
SDGs
Other Subjects
epidermal growth factor receptor; programmed death 1 ligand 1; protein tyrosine kinase inhibitor; CD274 protein, human; EGFR protein, human; epidermal growth factor receptor; programmed death 1 ligand 1; protein kinase inhibitor; adult; aged; Article; cancer prognosis; cancer resistance; cancer survival; clinical outcome; cohort analysis; controlled study; drug efficacy; female; gene mutation; human; immunohistochemistry; lung adenocarcinoma; major clinical study; male; priority journal; progression free survival; protein expression; protein expression level; retrospective study; Taiwanese; tumor microenvironment; biosynthesis; genetics; immunology; lung adenocarcinoma; lung tumor; middle aged; mutation; pathology; tumor microenvironment; very elderly; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; B7-H1 Antigen; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Tumor Microenvironment
Publisher
Elsevier Ltd
Type
journal article